Adherence to adrenalin autoinjector prescriptions and immunotherapy in anaphylaxis patients with special focus on venom allergy (A3PIA)

MD
Louise Parke
Department of Dermatology and Allergy Centre, Odense Research Centre for Anaphylaxis (ORCA), Odense University Hospital

Project management

Project status	Open



Data collection dates
Start	01.09.2019
End	01.01.2024

Project in numbers

OPEN survey/clinical data
Expected # of participants	3,000
Included # of participants	696





Included participants with specimens
Specimens

Adherence to adrenalin autoinjector prescriptions and immunotherapy in anaphylaxis patients with special focus on venom allergy (A3PIA)

Short summary

To perform a questionnaire study among patients seen during the 10 year period to evaluate the self-reported course and to link these data to retrieval rates for adrenaline (AAI) and venom immunotherapy (VIT).

Rationale

Primary endpoint: Self-reported course (duration, place for treatment, side-effects) of VIT, including causes for non-adherence to VIT. Secondary endpoints: Evaluation of the self-reported severity of the primary reaction, co-morbidity, symptoms by re-sting and QoL in relation to adherence to AAI and VIT.

Description of the cohort

Patients, seen in the Allergy Center between 1.1.2010-31.12.2019, with a diagnosis of venom allergy and registered for venom immunotherapy.

Data and biological material

Questionnaire study